Contract Option Exercises — September 03, 2026

Walgreens received a $290.9 million firm-fixed-price contract from the CDC, fully obligated and outlayed, providing high near-term revenue certainty of ~$96.9M annually through May 2025. The award via full and open competition signals competitive merit.

The contract's firm-fixed-price structure carries medium execution risk; any cost overruns on specialized medical support services would directly impact Walgreens' margins on this $290.9M award.

Walgreens faces margin risk on the $290.9M firm-fixed-price CDC contract if specialized medical support costs exceed expectations, given the service-oriented nature (NAICS 621999).

This single $290.9M award represents 100% of the period's total obligation, creating a concentration risk for Walgreens if the contract is not renewed after May 2025.

Walgreens' competitive win of the $290.9M CDC ICATT contract positions it for follow-on awards or program expansion, given the stable-to-growing civilian health sector funding.

The CDC's $290.9M fully obligated award to Walgreens demonstrates continued federal investment in specialized medical support services, despite broader budget uncertainty.

{"entity" => "Walgreens Boots Alliance (WBA)", "reason" => "Single large $290.9M CDC contract provides 3-year revenue visibility but carries fixed-price execution risk and renewal uncertainty.", "trigger" => "Q2 2025 earnings call for contract performance update; CDC ICATT program re-compete announcement in FY2025-2026"}